A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
for Multiple Myeloma
Drug: Elranatamab
34 locations incl. Coral Gables
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT06215118·Phase 1·Recruiting